7月24日，石药集团盘中上涨3.23%，报8.67港元，成交额1.77亿港元。
消息面上，石药集团7月22日公告称，其开发的SYS 6026注射液用于治疗HPV16或18型相关宫颈高级别鳞状上皮内病变的Ⅱ期临床试验已在中国正式启动。SYS 6026为治疗性mRNA疫苗，属治疗用生物制品1类，以HPV16和18亚型E6、E7蛋白为靶点。此外，公司近期利好密集：7月10日收到阿斯利康2500万美元研发里程碑付款；7月16日SYS 6043铂耐药晚期妇科癌Ⅲ期试验启动；7月14日创新药组合获突破性治疗认定，研发管线持续推进提振市场信心。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.